The industry looks set to bring the first vaccine for RSV to market in the coming year. But, which companies are leading the race, and why it would mark an important development for global health?
Editor-in-chief Jonah Comstock caught up with Alexandre LeVert, chairman, CEO, and co-founder of Osivax, on the sidelines of JP Morgan in San Francisco at the beginning of January of this year.&nbs
